• ERG overexpression in transgenic mice induces a transcriptional leukemia stem cell program characteristic of human AML.
Introduction
The ETS transcription factor ERG has been implicated as a major regulator of both normal and aberrant hematopoiesis [1] [2] . Further insights into ERG function in normal hematopoiesis have come from genome-wide binding site analysis, which revealed that ERG takes part in a heptad of transcription factors that preferentially bind to hematopoietic enhancers in the mouse multipotent hematopoietic progenitor cell line HPC-7 3 .
Aberrant ERG expression is strongly linked to cancer, as highlighted by its frequent involvement in chromosomal translocations associated with various malignancies such as TMPRSS2-ERG in prostate cancer, EWS-ERG in sarcoma and TLS-ERG in leukemia [4] [5] [6] . We have previously shown that ERG is a megakaryocytic oncogene 7 .
Moreover, ERG serves as an independent prognostic factor in cytogenetically normal AML and its expression is positively correlated with adverse outcome in both T-ALL and AML [8] [9] [10] . ERG is also included in a human leukemia stem cell gene signature that correlates with worse outcome in AML patients 11 . Despite this substantial evidence implicating ERG in leukemia development and maintenance, little is known about the molecular mechanisms employed by ERG in leukemic cells.
To address this issue, we generated transgenic mice with pan-haematopoietic ERG expression. Similar to human leukemias with increased expression of ERG, TgERG mice develop either T-lymphoid 12 or myeloid acute leukemias by 5 months of age.
Through combined gene expression and ChIP-Seq profiling, we now show that ERG overexpression in myeloid leukemias activates a stem cell signature characteristic of human AMLs. We also identify the oncogenic PIM1 kinase as a direct ERG target through its binding to a novel enhancer, and the RAS pathway as an indirect target of ERG. Finally, we demonstrate that pharmacological inhibition of either of these targets is therapeutically relevant.
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Methods

Transgenic mice and xenografts
TgERG mice were generated as previously described 12 . For transplantations, single cells were prepared from spleens of TgERG leukemic mice, washed in PBS and injected (5*10 5 per mouse) into tail veins of NOD scid Il2rgnull (NSG) mice.
Histology
Spleen and liver tissues were fixed in 4% neutral buffered formalin, transferred to 70% ethanol the next day, paraffin-embedded and H&E stained using standard protocols. Bone marrow cells were cytocentrifuged, fixed and stained with May
Grunwald/Giemsa stain (Sigma-Aldrich).
Immunophenotyping
Leukemic blasts taken from bone marrow of TgERG mice were washed in PBS with 0.05M EDTA and 0.1% BSA and then lineage depleted using a lineage depletion kit (Miltenyi Biotec). Lineage depleted leukemia cells were stained with PE-Cy7-conjugated anti-c-Kit, FITC-conjugated anti-Sca1 and APC-conjugated anti-CD150
antibodies (eBioscience). Cells were subsequently analyzed using the Gallios TM Flow cytometer and Kaluza® Flow Analysis Software (Beckman Coulter, Inc).
Gene expression profiling
Experiments were performed using Affymetrix Mouse gene 1.0 ST oligonucleotide arrays (Affymetrix, Santa Clara, CA). RNA samples were prepared from bone marrows of three TgERG mice (generated from 2 different founder lines), three wild type (wt) littermates and three pools of lineage depleted wt bone marrow cells. Total RNA from each sample was used to prepare biotinylated target cDNA, according to manufacturer's recommendations. A detailed description of the method is available in the supplemental methods. Raw data have been submitted to the National Center for Biotechnology Information to be accessed via the Gene Expression Omnibus portal (www.ncbi.nlm.nih.gov/geo; GEO record GSE49787)
Chromatin ImmunoPrecipitation
ChIP material was prepared from spleens of two TgERG mice with AML of identical immunophenotype. Tg1 on the background of wt Gata1 12 and Tg 2 on Gata1s background 13 . ChIP assays were performed as previously described using a rabbit polyclonal antibody raised against Erg-1/2/3 (clone C-17, Santa Cruz). As a control, non-specific Rabbit IgG (I5006; Sigma Aldrich) was used. Enrichment was first Raw and mapped sequence data have been submitted to the National Center for Biotechnology Information to be accessed via the Gene Expression Omnibus portal (www.ncbi.nlm.nih.gov/geo; GEO record GSE46554). Additional details can be found in the supplemental methods.
Enhancer activity assays
The Pim1 +10kb region was amplified from mouse genomic DNA using the restriction site introducing primers: cgcggatccGGGTTCAGATTAGCCATACCCacgcgtcgacAACACCCTACCCAGGGCTTC. This fragment was inserted downstream of the luciferase gene in pGL2 (Promega) or downstream from an SV40 minimal promoter in a construct containing a lacZ reporter cassette. The mutation constructs were made as previously described 14 and verified by sequencing. ETS site mutations were generated by PCR and verified by sequencing.
L8057 cells 15 were grown in DMEM/F-12 with glutamax (Invitrogen) in 15% FCS.
Stable transfections and luciferase assays were performed as described 16 .
F0 transgenic embryos were generated by pronuclear injection of reporter constructs by Cyagen Biosciences Inc. (Guangzhou, China). Embryos were harvested at embryonic day 11-12.5 and analyzed as described 17 . All animal studies were performed according to UK Home Office guidelines with Home Office approval.
Drugs
FTS (Salirasib), was kindly provided by Yoel Kloog (Tel-Aviv University). SGI-1776 was purchased from Selleck chemicals. For in vitro assays, both compounds were dissolved in DMSO and final concentrations were adjusted to 0.1% DMSO. For in vivo assays, FTS was prepared as described 18 .
Knockdown experiments
Stable knockdown of ERG in CMY cells was performed as previously described 7 . For PIM1 knockdown, TgERG leukemia cells (2.5*10 6 ) were transiently transfected with
Pim1 siRNA oligonucleotides or with Cy-5-conjugated non-targeting siRNA oligonucleotides (Sigma Aldrich) using AMAXA Nucleofector Kit V (Lonza)
according to the manufacturer's instructions and performing two consecutive pulses 24 hours apart.
Results
Transgenic ERG mice develop acute leukemia originating from an early myeloid progenitor
To examine the leukemogenic potential of ERG we generated transgenic mice expressing the human ERG3 hematopoietic isoform under the control of the vav promoter. ERG expression levels in the transgenic leukemia are within the range found in normal human CD34+ hematopoietic progenitors or in human AML cells ( Figure 1A ). We previously reported that about 30% of TgERG mice develop T- We next wanted to determine the relevance of TgERG myeloid leukemias to the human disease. Using GSEA, we found significant enrichment of high-ERG expressing human AML signature 9 in the gene expression profile of TgERG leukemia compared to the wt control ( Figure 1H Figure 1I , Figure S3) sample. 85% of the peaks detected in Tg2 leukemia sample were also detected in Tg1 leukemia ( Figure 2C ), confirming that ERG binding was very similar in the two samples. We therefore performed all subsequent analysis on the 3201 regions bound by ERG in both samples. Of these high-confidence regions, 59% locate to promoters, 23% to intragenic and 18% to intergenic regions respectively ( Figure 2D ). 
Integrated genomic analysis reveals an ERG regulated transcriptional program characteristic of human leukemia progenitors.
To identify candidate ERG targets, the high confidence ERG peaks were mapped to 3433 genes. We next integrated the ChIP-Seq and expression data by matching all ERG bound genes to the expression data and creating expression profiles of TgERG leukemia compared to wt lin -cells ( Figure 3A ). Unsupervised clustering based on expression data for the ERG candidate target genes partitioned the samples into leukemic and non-leukemic cell types, consistent with the notion that elevated ERG drives expression changes relevant to the disease phenotype. DAVID functional annotations tool 29 suggests that ERG directly regulates the expression of a large group of transcription regulators in TgERG leukemia compared to wt lin -cells (Table S1) and GSEA confirmed that the upregulated transcription factors are enriched in human AML progenitors compared to normal hematopoietic progenitors ( Figure 3B ). Thus, ERG directly activates a series of transcription factors that characterize human AML progenitors.
qRT-PCR validation confirmed that Gata2 and Hey2 (hairy/enhancer-of-split related with YRPW motif 2) are highly upregulated TFs in TgERG leukemia ( Figure 3C ).
Importantly, this upregulation was significant also when compared to wild type MEPs, suggesting a role for these TFs specifically in ERG driven leukemia and not simply as markers of this progenitor cell ( Figure 3C ). GATA2 is an important 
Activation of RAS in TgERG leukemia
Analysis of direct ERG targets through integrated expression array and ChIP-Seq profiling allowed us to identify signaling pathways that are likely key players in ERG driven myeloid leukemia. Using DAVID functional annotations tool, we found upregulation of several cancer related signaling pathways in the Tg leukemia, with the MAPK pathway being the most enriched ( Figure 4A ). qRT-PCR confirmed elevated expression of MAPK pathway genes such as the dual specificity kinase, Map2k3, the transforming growth factors Tgfb1 and Tgfa, and the growth factor receptor binding protein, Grb2 ( Figure S4 ), which is known to recruit guanine nucleotide exchange factors that facilitate activation of the small GTPase RAS
34
. Accordingly, RAS is activated in TgERG leukemias as depicted by elevated levels of active Ras-GTP and its downstream effectors ( Figure 4B ). In AML, RAS is frequently activated by somatic mutation occurring in codons 12, 13 and 63 35 . However, no such mutations were found in TgERG leukemia in the three RAS isoforms: H, K or N-RAS ( Figure   4C ), confirming the activation of the pathway by an upstream transcriptional program.
To evaluate the role of Ras in TgERG leukemia cells we used a specific Ras inhibitor, ( Figure S5 ). The effective FTS dose also caused a significant decrease in active Ras-GTP levels in leukemia infiltrated spleens ( Figure 4F ). These results indicate that RAS inhibition may serve as a therapeutic approach in AML patients expressing high levels of ERG.
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Pim1 kinase is a direct ERG target activated through a previously unknown +10 enhancer
As shown in Figure 4A , integrative genomic analysis of direct ERG targets revealed upregulation of AML related genes. One of these genes, Pim1, encodes an oncogenic serine/threonine kinase 39 . We confirmed increased expression of Pim1 RNA and protein in independent TgERG mouse samples as well as in the human AMKL cell line CMY in which ERG is highly expressed ( Figure 5A ,B). PIM1 levels were lower in CMK cells, that express lower levels of ERG and upon knockdown of ERG in CMY cells ( Figure 5A , B), confirming that ERG regulates PIM1 expression in leukemia.
Magistroni et al recently showed that ERG upregulates PIM1 in prostate cancer cells via direct binding to the PIM1 promoter 40 . Analysis of our ERG Chip-Seq data in TgERG leukemias revealed weak binding to Pim1 promoter but a much stronger ERG peak about 10 kb downstream of the promoter ( Figure 5C ). This region contains several evolutionarily conserved transcription factor consensus binding motifs including ETS motifs ( Figure S6 ), suggesting the presence of an enhancer element.
Notably, the corresponding PIM1+13 region in human CD34+ cells is bound by a heptad of TFs, including ERG, known to activate stem cell programs in AML
24
, and displays open chromatin marks ( Figure 5D ). In addition, ERG binds the PIM1 +13 region in the human AML cell lines, KG-1 and ME-1 ( Figure S7 ).
To test whether this region has enhancer activity, a DNA fragment corresponding to the ERG-bound region (+10kb region) was inserted downstream of a minimal promoter/luciferase reporter cassette and assayed following stable transfection in the murine megakaryoblastic cell line L8057 15 . Inclusion of the Pim1 +10kb region caused a 4 to 6-fold increase of promoter activity which was almost completely abolished when the two conserved ETS motifs were mutated ( Figure 5E ). To confirm bona-fide enhancer activity of the Pim1 +10 region, we generated transgenic mouse
embryos with a corresponding lacZ reporter construct. Analysis of E11.5 midgestation embryos confirmed in-vivo activity in fetal liver hematopoietic cells, some of which displayed megakaryocyte-like characteristics ( Figure 5F ). The enhancer element also directed expression to the eye which reflects Pim1 known expression in the mouse embryonic neural retina 41 . Taken together, these data suggest that ERG expression in the Tg leukemias mediates elevated levels of Pim1 through a previously unknown Pim1 3' enhancer.
Pim1 kinase is a potential therapeutic target in ERG-expressing AML
PIM inhibitors have been evaluated in both preclinical and clinical trials for hematological malignancies [42] [43] (ClinicalTrials.gov NCT00848601, NCT01239108).
To test Pim1 as a potential therapeutic target of high ERG expressing leukemias we Figure S8 ), high expression of both genes is significantly associated with decreased survival rates ( Figure 6I ). Thus PIM1 may be a highly relevant therapeutic target in these leukemias.
Discussion
The ETS transcription factor ERG is an independent prognostic factor in AML and T-ALL [8] [9] [10] , yet it is unclear whether its expression is a marker of the early differentiation block of the leukemic cells or whether ERG actively contributes to the leukemic phenotype. Although we and others 7, 44 have previously shown that ERG is a ERG is a member of a prognositcally significant human leukemia stem cell gene signature 11 . Enrichment of a stem/progenitor signature in our Tg-ERG mouse AML suggests that ERG may not simply be a marker but instead constitutes an important driver of the leukemia stem cell signature. Of note, direct ERG target genes in the TgERG leukemia include transcription factors such as GATA2 and HEY2, with GATA motifs also being highly enriched within the regions bound by ERG. GATA2
is a key regulator of hematopoietic stem cell 32 and megakaryocyte development 45 , and high GATA2 expression has recently been reported as a poor prognostic factor in pediatric AML 31 . HEY2 is largely recognized as a regulator of cardiovascular Myc has been suggested to amplify the output of existing gene expression programs and thereby reduce rate-limiting constraints for tumor cell growth and proliferation 47 Interestingly, we found that the most downregulated pathways in TgERG leukemia are purine and pyrimidine metabolism (Table S2) . Nucleotide deficiency has recently been shown to promote genomic instability, a key factor in the first stages of cancer formation 48 . Therefore, it is possible that over expression of ERG in hematopoietic cells contributes to genomic instability, which in conjunction with other affected pathways, may drive the leukemogenic process.
A major goal of this work was to identify ERG targets that may be pharmaceutically targeted. The most enriched signaling pathway in TgERG leukemia is the MAPK pathway, a pathway known to be downstream of the small GTPase, RAS, which is indeed activated in the Tg leukemia ( Figure 4B ). Ras is a well-known oncogene, and is constitutively activated by common somatic mutations in about 20% of AML cases 35 . Consistent with transcriptional activation we found no activating mutations in Ras, We also identified PIM1 kinase as a direct ERG target activated through a novel enhancer which we further characterized in mouse and human cells. The PIM1 serine/threonine kinase, first described as a proviral integration site in murine T-cell lymphomas 49 , is frequently overexpressed in various malignancies including hematological 50 and prostate cancers 51 . In AML, PIM1 regulates cell proliferation and survival as well as homing and migration 43, [52] [53] . We show the prognostic relevance of PIM1 upregulation in high ERG expressing AML by the significantly decreased survival of these patients. We therefore explored the effects of Pim1 inhibition in TgERG leukemia by a PIM inhibitor, SGI-1776 43 . SGI-1776 has been shown to inhibit growth and promote apoptosis of hematopoietic and prostate cancer cells 43, 54 .
It is also a potent inhibitor of FLT3 and TRKA, neither of which are expressed in were terminated due to dose limiting toxicity, the beneficial effect of PIM1 inhibition in AML preclinical models has been established [42] [43] .
TgERG leukemia (not shown). SGI-1776 treatment inhibited growth and induced
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